Educational dose math only — not medical advice, not a product recommendation, and not a pass/fail on whether a supplement will work for you.
0 100% 150%+

—

Enter label dose

Trial reference

From your label

Per-day total — not per serving unless you take one serving

Enter your label dose — the gauge updates instantly.

Two doses of branded Mitopure in middle-aged adults for four months. The primary endpoint — peak power output — was not met. Muscle strength rose about 12%, with improvements in peak VO2, six-minute walk, plasma acylcarnitines and CRP as secondary outcomes. Manufacturer-run trial on a specific synthesised preparation.

Educational only — not medical advice. Disclaimer.

Want the outcome before the arithmetic? The reason check opens any registry entry on this page with its trial result first, then compares your daily intake with the studied amount.

Trial floors

Primary

ATLAS trial, branded Mitopure · 500–1,000 mg over 4 months (limited evidence · how we grade this) · Secondary outcomes only — Two doses of branded Mitopure in middle-aged adults for four months. The primary endpoint — peak power output — was not met. Muscle strength rose about 12%, with improvements in peak VO2, six-minute walk, plasma acylcarnitines and CRP as secondary outcomes. Manufacturer-run trial on a specific synthesised preparation.

Other floors

  • Older adults, 1000 mg · 1,000 mg over 4 months (limited evidence · how we grade this) · Primary endpoint missed — Adults 65-90. Both primary endpoints failed — six-minute walk distance and maximal ATP production in hand muscle were no better than placebo. Secondary muscle endurance in two muscles and plasma biomarkers did improve. Safe and well tolerated.

  • Safety and mitochondrial gene signature · 500–1,000 mg over 4 weeks (limited evidence · how we grade this) · Primary endpoint missed — Sedentary older adults. This trial established tolerability and showed the compound reaches muscle and shifts mitochondrial gene expression. There was no strength or performance endpoint at all — it answers "does oral urolithin A do anything in tissue", not "will I be stronger".

  • Endothelial function trial (1000 mg) · 1,000 mg over 4 weeks (limited evidence · how we grade this) · Primary endpoint missed — Double-blind placebo-controlled single-site trial in adults 40-64 with obesity; the primary endpoint, brachial artery flow-mediated dilation, did not separate from placebo, nor did secondary peripheral endothelial measures. Exploratory cerebrovascular hemodynamics moved in the urolithin group. Cited by our urolithin A vs NMN guide.

Label reading notes

  • Every human trial to date used a synthesised branded preparation (Mitopure). A generic urolithin A powder at the same milligram count is not covered by this evidence.
  • Pomegranate juice or ellagitannin extracts are not equivalent — only some people carry the gut bacteria that convert ellagitannins to urolithin A, which is the reason direct supplementation exists.
  • Shelf comparison is switched off for this ingredient: too few labelled products, and branded versus generic material is not comparable on milligrams alone. Whether it should be comparable is an open question.
  • Every efficacy trial in this file missed its prespecified primary endpoint. The human case rests on secondary outcomes.